Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Imugene (IMU) receives US FDA Investigational New Drug (IND) approval for two new drug candidates
  • The first approval gives Imugene permission to begin patient recruitment and dosing for the nextHERIZON study in advanced gastric cancer
  • The second allows the initiation of a Phase 1 clinical trial of the company’s oncolytic virotherapy candidate, VAXINIA
  • The company says achieving concurrent approvals for its programs is an outstanding result for the team
  • Imugene last traded at 51.5 cents on December 10

Imugene (IMU) has received US Food and Drug Administration Investigational New Drug (IND) approval for two new drug candidates.

The first grants approval to initiate a new phase 2 clinical trial of its immunotherapy candidate, HER-Vaxx.

The approval gives Imugene permission to start patient recruitment and dosing for the nextHERIZON study in HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction, commonly known as Advanced Gastric Cancer (AGC).

The nextHERIZON study is designed to analyse the safety and efficacy of the drug to support the further development of HER-Vaxx in cancer after progression with trastuzumab. All patients must have received trastuzumab and progressed after one litre to be eligible for enrolment.

The company previously found increasing the number of cytotoxic immune cells within the tumour microenvironment (TME) via the use of immunotherapies such as HER-Vaxx has been promising.

Based on pre-clinical data, HER-Vaxx may also synergize with PD-1 targeting immune checkpoint inhibitor pembrolizumab and therefore serve as a potentially better tolerated and chemotherapy-free treatment opportunity in metastatic patients.

The second approval allows the initiation of a Phase 1 clinical trial of the company’s oncolytic virotherapy candidate, VAXINIA.

The approval allows Imugene to start patient recruitment and dosing in a Phase 1 clinical trial for a metastatic or advanced solid tumors study in multiple solid tumour type patients.

This is an open-label, dose-escalation, multi-centre phase I study evaluating the safety of CF33-hNIS,which can be administered via either intratumourally (IT) or intravenously (IV).

“Accomplishing this goal speaks to the perseverance and dedication of Imugene’s and City of Hope’s research and development teams as we continue to build on our clinical and commercial potential,” said Imugene MD & CEO Leslie Chong.

“To achieve two INDs for our programs concurrently is an outstanding result for the team.”

Imugene last traded at 51.5 cents on December 10.

IMU by the numbers
More From The Market Herald

" Hydrogen industry marks milestone with world first shipment of hydrogen

The Australian hydrogen industry just marked a milestone with the world's first shipment of liquefied hydrogen…
Prime Minister Scott Morrison. Source: APP

" Australia and PNG sign $580m agreement for PNG port infrastructure

The Australian Government signs an agreement with Papua New Guinea for $580 million worth of upgrades…

" Serbia scraps $3.3b Rio Tinto (ASX:RIO) lithium mine following weeks of protests

The Serbian government has this week bowed to local protestors and pulled the plug on Rio…

" Post-Delta jobs boom sees unemployment reach pre-GFC lows

Over 65,000 Australians found jobs in the first two weeks of December as unemployment shrank to…